

RGFP966

Catalog No: tcsc1628



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1357389-11-7

Formula:

$C_{21}H_{19}FN_4O$

Pathway:

Epigenetics;Cell Cycle/DNA Damage

Target:

HDAC;HDAC

Purity / Grade:

>98%

Solubility:

H₂O :

Observed Molecular Weight:

362.4

Product Description


RGFP966 is a highly selective **HDAC3** inhibitor with an **IC₅₀** of 80 nM and shows no inhibition to other HDACs at concentrations up to

15 μ M.

IC50 & Target: IC50: 80 nM (HDAC3)^[1]

In Vitro: RGFP966 potently and selectively inhibits HDAC 3 with IC₅₀ of 0.21 μ M in RAW 264.7 macrophages, while HDACs 1 (IC₅₀ =5.6 μ M), 2 (9.7 μ M) and 8 (>100 μ M), indicating a good level of selectivity for HDAC 3. The mRNA levels of HDACs 1, 2 and 3 are not significantly affected by RGFP966 in RAW 264.7 macrophages, whereas the HDAC 1 and HDAC 2 protein levels are slightly, though significantly, reduced upon RGFP966 treatment. Moreover, RGFP966 significantly reduced the transcriptional activity of NF- κ B p65, whereas NF- κ B p65 acetylation and localization remain unaltered^[2].

In Vivo: RGFP966 (10 and 25 mg/kg) treatment significantly improves body weight, rotarod performance and several measures of motor function in the open field locomoter test^[3]. RGFP966 at a 10 mg/kg dose penetrates the blood-brain barrier into rat auditory cortex with typical pharmacokinetics, which together establish feasibility for the modulation of A1 plasticity due to action in the auditory cortex^[4].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!